Duolingo, Inc. DUOL
5 trading plans running, 34 Form 144 notices for $54.2M
10-Q, 10-K and Form 144What DUOL's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From May 27, 2025 to Dec 31, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| Natalie Glance Chief Engineering Officer |
Adopted 10b5-1 plan | Sep 4, 2026 | 10-Q Nov 4, 2026 | ||
What the company wroteOn September 4, 2026, Natalie Glance, Chief Engineering Officer, entered into a 10b5-1 sales plan (the “Glance 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act, providing for (i) the sale of the net number of shares of Class A common stock underlying 19,283 unvested restricted stock units received after giving effect to the number of shares automatically sold to satisfy tax withholding obligations on each applicable vesting date (such total number of shares covered under clause (i) is not determinable) and (ii) the sale of 16,866 shares of Class A common stock. The Glance 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 31, 2027, (2) the date on which all trades set forth in the Glance 10b5-1 Sales Plan have been executed, or (3) such time as the Glance 10b5-1 Sales Plan is otherwise terminated according to its terms. | |||||
| Stephen Chen General Counsel |
Adopted 10b5-1 plan | Jun 14, 2026 | 10-Q Aug 6, 2026 | ||
What the company wroteOn June 14, 2026, Stephen Chen, General Counsel, entered into a 10b5-1 sales plan (the “Chen 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for (i) the sale of the net number of shares of Class A common stock underlying 12,524 unvested restricted stock units received after giving effect to the number of shares automatically sold to satisfy tax withholding obligations on each applicable vesting date (such total number of shares covered under clause (i) is not determinable) and (ii) the sale of 12,696 shares of Class A common stock. The Chen 10b5-1 Sales Plan will remain in effect until the earlier of (1) August 14, 2027, (2) the date on which all trades set forth in the Chen 10b5-1 Sales Plan have been executed, or (3) such time as the Chen 10b5-1 Sales Plan is otherwise terminated according to its terms. | |||||
| William "Bing" Gordon member of our Board of Directors |
Ended 10b5-1 plan | Jun 9, 2026 | 10-Q Aug 6, 2026 | ||
What the company wroteOn June 9, 2026, William "Bing" Gordon, a member of our Board of Directors, modified his Rule 10b5-1 sales plan that was originally adopted on December 11, 2025. The modified trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and provides for the sale of up to 40,000 shares of the Company’s Class A common stock. The trading arrangement will remain in effect until the earlier of (i) June 30, 2027, (ii) the completion of all authorized transactions, or (iii) termination in accordance with its terms. | |||||
| Dr. Luis von Ahn Chief Executive Officer and member of the Company’s Board of Directors |
Adopted 10b5-1 plan | Jun 2, 2026 | 10-Q Aug 6, 2026 | ||
What the company wroteOn June 2, 2026, Dr. Luis von Ahn, Chief Executive Officer and member of the Company’s Board of Directors, and the Luis von Ahn Foundation, entered into a 10b5-1 sales plan (the “von Ahn 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act, pursuant to which a maximum aggregate amount of up to 626,000 shares of the Company’s Class A common stock may be sold, consisting of (i) up to 226,000 shares issuable upon the exercise of vested stock options held by Dr. von Ahn and (ii) up to 400,000 shares held by Dr. von Ahn. Additionally, under the von Ahn 10b5-1 Sales Plan, up to 54,000 shares held by the Luis von Ahn Foundation) may be sold. The von Ahn 10b5-1 Sales Plan will remain in effect until the earlier of (1) September 15, 2027, (2) the date on which all trades set forth in the von Ahn 10b5-1 Sales Plan have been executed, or (3) such time as the von Ahn 10b5-1 Sales Plan is otherwise terminated or expires according to its terms. | |||||
| William "Bing" Gordon member of our Board of Directors |
Ended 10b5-1 plan | Dec 11, 2025 | 10-K Feb 27, 2026 | ||
What the company wroteOn December 11, 2025, William "Bing" Gordon, a member of our Board of Directors, modified his Rule 10b5-1 sales plan (the “Gordon 10b5-1 Sales Plan”) that was originally adopted on June 13, 2025, to extend the expiration date to December 31, 2026. The modified trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and provides for the sale of up to 40,000 shares of the Company’s Class A common stock. The trading arrangement will remain in effect until the earlier of (i) December 31, 2026, (ii) the completion of all authorized transactions, or (iii) termination in accordance with its terms. | |||||
| Natalie Glance Chief Engineering Officer |
Adopted 10b5-1 plan | Sep 15, 2025 | 10-Q Nov 6, 2025 | ||
What the company wroteOn September 15, 2025, Natalie Glance, Chief Engineering Officer, entered into a 10b5-1 sales plan (the “Glance 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for (i) exercise of vested stock options and the associated sale of up to 14,759 shares of the Company’s Class A common stock, (ii) the sale of 3,285 shares of Class A common stock, and (iii) the net number of shares of Class A common stock underlying 16,723 unvested restricted stock units after giving effect to the number of shares to be sold outside of the Glance 10b5-1 Plan to satisfy tax withholding obligations (which net amount is not currently determinable). The Glance 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 31, 2026, (2) the date on which all trades set forth in the Glance 10b5-1 Sales Plan have been executed, or (3) such time as the Glance 10b5-1 Sales Plan is otherwise terminated according to its terms. | |||||
| Dr. Severin Hacker Chief Technology Officer and member of the Company’s Board of Directors |
Adopted 10b5-1 plan | Sep 12, 2025 | 10-Q Nov 6, 2025 | ||
What the company wroteOn September 12, 2025, each of Dr. Severin Hacker, Chief Technology Officer and member of the Company’s Board of Directors, the SBH Trust dated March 10, 2020 (“SBH Trust”) and the Severin Hacker Foundation, entered into a joint 10b5-1 sales plan (the “Hacker 10b5-1 Sales Plan”). The Hacker 10b5-1 Sales Plan, which is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act, will commence trading once Dr. Hacker’s 10b5-1 sales plan dated September 11, 2024 ends. Under the Hacker 10b5-1 Sales Plan, a maximum aggregate of up to 515,000 shares of the Company’s Class A common stock may be sold, consisting of (i) the net number of shares of Class A common stock issuable upon the exercise of 50,000 vested stock options held by Dr. Severin Hacker that remain unsold pursuant to Mr. Hacker’s 10b5-1 sales plan dated September 11, 2024 (which net amount is not currently determinable), (ii) up to 465,000 shares held by SBH Trust, and (iii) up to 50,000 shares held by the Severin Hacker Foundation). The Hacker 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 31, 2027, (2) the date on which all trades set forth in the Hacker 10b5-1 Sales Plan have been executed, or (3) such time as the Hacker 10b5-1 Sales Plan is otherwise terminated or expires according to its terms. | |||||
| William Gordon member of our Board of Directors |
Adopted 10b5-1 plan | Jun 13, 2025 | 10-Q Aug 7, 2025 | ||
What the company wroteOn June 13, 2025, William Gordon, a member of our Board of Directors, entered into a 10b5-1 sales plan (the “Gordon 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing (i) the exercise of vested stock options and the associated sale of up to 10,000 shares of the Company’s Class A common stock, and (ii) the sale of 30,000 shares of Class A common stock. The Gordon 10b5-1 Sales Plan will remain in effect until the earlier of (1) September 30, 2026, (2) the date on which all trades set forth in the Gordon 10b5-1 Sales Plan have been executed, or (3) such time as the Gordon 10b5-1 Sales Plan is otherwise terminated according to its terms. | |||||
| Dr. Luis von Ahn Chief Executive Officer |
Adopted 10b5-1 plan | Jun 11, 2025 | 10-Q Aug 7, 2025 | ||
What the company wroteOn June 11, 2025, Dr. Luis von Ahn, Chief Executive Officer and member of the Company’s Board of Directors, and the Luis von Ahn Foundation, entered into a 10b5-1 sales plan (the “von Ahn 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act, pursuant to which a maximum aggregate of up to 431,000 shares of the Company’s Class A common stock may be sold, consisting of (i) up to 226,000 shares issuable upon the exercise of vested stock options held by Dr. von Ahn, (ii) up to 200,000 shares held by Dr. von Ahn, and (iii) up to 5,000 shares held by the Luis von Ahn Foundation). The von Ahn 10b5-1 Sales Plan will remain in effect until the earlier of (1) September 15, 2026, (2) the date on which all trades set forth in the von Ahn 10b5-1 Sales Plan have been executed, or (3) such time as the von Ahn 10b5-1 Sales Plan is otherwise terminated or expires according to its terms. | |||||
| Robert Meese Chief Business Officer |
Adopted 10b5-1 plan | Jun 9, 2025 | 10-Q Aug 7, 2025 | ||
What the company wroteOn June 9, 2025, Robert Meese, Chief Business Officer, entered into a 10b5-1 sales plan (the “Meese 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for (i) the sale of the net number of shares of Class A common stock underlying 3,151 unvested restricted stock units received after giving effect to the number of shares automatically sold to satisfy tax withholding obligations on each applicable vesting date (such total number of shares covered under clause (i) is not determinable) and (ii) the sale of 18,296 shares of Class A common stock. The Meese 10b5-1 Sales Plan will remain in effect until the earlier of (1) May 29, 2026, (2) the date on which all trades set forth in the Meese 10b5-1 Sales Plan have been executed, or (3) such time as the Meese 10b5-1 Sales Plan is otherwise terminated according to its terms. | |||||
| Gillian Munson member of our Board of Directors |
Adopted 10b5-1 plan | May 27, 2025 | 10-Q Aug 7, 2025 | ||
What the company wroteOn May 27, 2025, Gillian Munson, a member of our Board of Directors, entered into a 10b5-1 sales plan (the “Munson 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for the potential exercise of vested stock options and the associated sale of up to 3,062 shares of the Company’s Class A common stock. The Munson 10b5-1 Sales Plan will remain in effect until the earlier of (1) February 27, 2026, (2) the date on which all trades set forth in the Munson 10b5-1 Sales Plan have been executed, or (3) such time as the Munson 10b5-1 Sales Plan is otherwise terminated according to its terms. | |||||
| Matthew Skaruppa Chief Financial Officer |
Adopted 10b5-1 plan | May 27, 2025 | 10-Q Aug 7, 2025 | ||
What the company wroteOn May 27, 2025, Matthew Skaruppa, Chief Financial Officer, entered into a 10b5-1 sales plan (the “Skaruppa 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for (i) the sale of the net number of shares of Class A common stock underlying 23,429 unvested restricted stock units received after giving effect to the number of shares automatically sold to satisfy tax withholding obligations on each applicable vesting date (such total number of shares covered under clause (i) is not determinable), (ii) the sale of 6,500 shares of Class A common stock and (iii) exercise of vested stock options and the associated sale of up to 1,378 shares of the Company’s Class A common stock. The Skaruppa 10b5-1 Sales Plan will remain in effect until the earlier of (1) August 14, 2026, (2) the date on which all trades set forth in the Skaruppa 10b5-1 Sales Plan have been executed, or (3) such time as the Skaruppa 10b5-1 Sales Plan is otherwise terminated according to its terms. | |||||
| Stephen Chen General Counsel |
Adopted 10b5-1 plan | May 27, 2025 | 10-Q Aug 7, 2025 | ||
What the company wroteOn May 27, 2025, Stephen Chen, General Counsel, entered into a 10b5-1 sales plan (the “Chen 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for (i) the sale of the net number of shares of Class A common stock underlying 11,187 unvested restricted stock units received after giving effect to the number of shares automatically sold to satisfy tax withholding obligations on each applicable vesting date (such total number of shares covered under clause (i) is not determinable) and (ii) the sale of 10,996 shares of Class A common stock. The Chen 10b5-1 Sales Plan will remain in effect until the earlier of (1) August 14, 2026, (2) the date on which all trades set forth in the Chen 10b5-1 Sales Plan have been executed, or (3) such time as the Chen 10b5-1 Sales Plan is otherwise terminated according to its terms. | |||||
| James Shelton member of our Board of Directors |
Adopted 10b5-1 plan | Dec 9, 2024 | 10-K Feb 28, 2025 | ||
What the company wroteOn December 9, 2024, James Shelton, a member of our Board of Directors, entered into a 10b5-1 sales plan (the “Shelton 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for (i) the potential exercise of vested stock options and the associated sale of up to 20,000 shares of the Company’s Class A common stock, and (ii) the sale of up to 895 shares of Class A common stock underlying unvested restricted stock units. The Shelton 10b5-1 Sales Plan will remain in effect until the earlier of (1) August 29, 2025, (2) the date on which all trades set forth in the Shelton 10b5-1 Sales Plan have been executed, or (3) such time as the Shelton 10b5-1 Sales Plan is otherwise terminated according to its terms. | |||||
| Robert Meese Chief Business Officer |
Adopted 10b5-1 plan | Dec 9, 2024 | 10-K Feb 28, 2025 | ||
What the company wroteOn December 9, 2024, Robert Meese, Chief Business Officer, entered into a 10b5-1 sales plan (the “Meese 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for (i) the sale of the net number of shares of Class A common stock underlying 3,543 restricted stock units received after giving effect to the number of shares automatically sold under the Meese 10b5-1 Sales Plan to satisfy tax withholding obligations on each applicable vesting date (such total number of shares covered under clause (i) is not determinable) and (ii) the sale of 18,080 shares of Class A common stock shares. The Meese 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 31, 2025, (2) the date on which all trades set forth in the Meese 10b5-1 Sales Plan have been executed, or (3) such time as the Meese 10b5-1 Sales Plan is otherwise terminated according to its terms. | |||||
| Gillian Munson member of our Board of Directors |
Adopted 10b5-1 plan | Dec 7, 2024 | 10-K Feb 28, 2025 | ||
What the company wroteOn December 7, 2024, Gillian Munson, a member of our Board of Directors, entered into a 10b5-1 sales plan (the “Munson 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for the potential exercise of vested stock options and the associated sale of up to 5,000 shares of the Company’s Class A common stock. The Munson 10b5-1 Sales Plan will remain in effect until the earlier of (1) August 14, 2025, (2) the date on which all trades set forth in the Munson 10b5-1 Sales Plan have been executed, or (3) such time as the Munson 10b5-1 Sales Plan is otherwise terminated according to its terms. | |||||
| Natalie Glance Chief Engineering Officer |
Adopted 10b5-1 plan | Nov 14, 2024 | 10-K Feb 28, 2025 | ||
What the company wroteOn November 14, 2024, Natalie Glance, Chief Engineering Officer, entered into a 10b5-1 sales plan (the “Glance 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for (i) the sale of the net number of shares of Class A common stock underlying 22,099 unvested restricted stock units received after giving effect to the number of shares automatically sold to satisfy tax withholding obligations on each applicable vesting date (such total number of shares covered under clause (i) is not determinable) and (ii) the sale of 14,855 shares of Class A common stock shares. The Glance 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 31, 2025, (2) the date on which all trades set forth in the Glance 10b5-1 Sales Plan have been executed, or (3) such time as the Glance 10b5-1 Sales Plan is otherwise terminated according to its terms. | |||||
| Dr. Luis von Ahn Chief Executive Officer and member of the Company’s Board of Directors |
Adopted 10b5-1 plan | Sep 12, 2024 | 10-Q/A Dec 16, 2024 | ||
What the company wroteOn September 12, 2024, Dr. Luis von Ahn, Chief Executive Officer and member of the Company’s Board of Directors, and the Luis von Ahn Foundation, entered into a 10b5-1 sales plan (the “von Ahn 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act, pursuant to which a maximum aggregate of up to 237,750 shares of the Company’s Class A common stock may be sold (up to 219,000 shares by Dr. von Ahn and up to 18,750 shares by the Luis von Ahn Foundation). The von Ahn 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 15, 2025, (2) the date on which all trades set forth in the von Ahn 10b5-1 Sales Plan have been executed, or (3) such time as the von Ahn 10b5-1 Sales Plan is otherwise terminated or expires according to its terms. | |||||
| Dr. Severin Hacker Chief Technology Officer and Director |
Adopted 10b5-1 plan | Sep 10, 2024 | 10-Q/A Dec 16, 2024 | ||
What the company wroteOn September 10, 2024, Dr. Severin Hacker, Chief Technology Officer and Director, entered into a 10b5-1 sales plan (the “Hacker 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for the potential exercise of vested stock options and the associated sale of up to 504,248 shares of the Company’s Class A common stock. The Hacker 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 4, 2025, (2) the date on which all trades set forth in the Hacker 10b5-1 Sales Plan have been executed, or (3) such time as the Hacker 10b5-1 Sales Plan is otherwise terminated according to its terms. | |||||
| Dr. Severin Hacker Chief Technology Officer and Director |
Adopted 10b5-1 plan | Sep 10, 2024 | 10-Q Nov 7, 2024 | ||
What the company wroteOn September 10, 2024, Dr. Severin Hacker, Chief Technology Officer and Director, entered into a 10b5-1 sales plan (the “Hacker 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for the potential exercise of vested stock options and the associated sale of up to 504,248 shares of the Company’s Class A common stock. The Hacker 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 4, 2025, (2) the date on which all trades set forth in the Hacker 10b5-1 Sales Plan have been executed, or (3) such time as the Hacker 10b5-1 Sales Plan is otherwise terminated according to its terms. | |||||
| Stephen Chen General Counsel |
Adopted 10b5-1 plan | May 31, 2024 | 10-Q Aug 8, 2024 | ||
What the company wroteOn May 31, 2024, Stephen Chen, General Counsel, entered into a 10b5-1 sales plan (the “Chen 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for (i) the potential exercise of vested stock options and the associated sale of up to 7,382 shares of the Company’s Class A common stock and, (ii) the sale of the net number of shares of Class A common stock underlying 10,898 restricted stock units received after giving effect to the number of shares automatically sold under the Chen 10b5-1 Sales Plan to satisfy tax withholding obligations on each applicable vesting date (such total number of shares covered under clause (ii) is not determinable), and (iii) the sale of 14,108 shares of Class A common stock shares. The Chen 10b5-1 Sales Plan will remain in effect until the earlier of (1) August 14, 2025, (2) the date on which all trades set forth in the Chen 10b5-1 Sales Plan have been executed, or (3) such time as the Chen 10b5-1 Sales Plan is otherwise terminated according to its terms. | |||||
| Matthew Skaruppa Chief Financial Officer |
Adopted 10b5-1 plan | May 22, 2024 | 10-Q Aug 8, 2024 | ||
What the company wroteOn May 22, 2024, Matthew Skaruppa, Chief Financial Officer, entered into a 10b5-1 sales plan (the “Skaruppa 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and providing for (i) the potential exercise of vested stock options and the associated sale of up to 69,049 shares of the Company’s Class A common stock, (ii) the sale of the net number of shares of Class A common stock underlying 27,503 restricted stock units received after giving effect to the number of shares automatically sold under the Skaruppa 10b5-1 Sales Plan to satisfy tax withholding obligations on each applicable vesting date (such total number of shares covered under clause (ii) is not determinable) and (iii) the sale of 27,503 shares of Class A common stock shares. The Skaruppa 10b5-1 Sales Plan will remain in effect until the earlier of (1) August 14, 2025, (2) the date on which all trades set forth in the Skaruppa 10b5-1 Sales Plan have been executed, or (3) such time as the Skaruppa 10b5-1 Sales Plan is otherwise terminated according to its terms. | |||||
| Robert Meese Chief Business Officer |
Adopted 10b5-1 plan | Mar 13, 2024 | 10-Q May 9, 2024 | ||
What the company wroteOn December 11, 2023, the 10b5-1 sales plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act entered into by Robert Meese, Chief Business Officer, on September 8, 2023 expired in accordance with its terms upon the sale of the maximum aggregate number of shares of Class A common stock covered by such plan. On March 13, 2024, Mr. Meese entered into a 10b5-1 sales plan (the “Meese 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act which provides for the potential exercise of vested stock options and the associated sale of up to 17,675 shares of the Company’s Class A common stock. The Meese 10b5-1 Sales Plan will remain in effect until the earlier of (1) July 31, 2025, (2) the date on which an aggregate of 17,675 shares of the Company’s Class A common stock have been sold under the Meese 10b5-1 Sales Plan, or (3) such time as the Meese 10b5-1 Sales Plan is otherwise terminated or expires according to its terms. | |||||
| Amy Bohutinsky member of our Board of Directors |
Adopted 10b5-1 plan | Dec 4, 2023 | 10-K Feb 29, 2024 | ||
What the company wroteOn December 4, 2023, Amy Bohutinsky, member of our Board of Directors, entered into a 10b5-1 sales plan (the “Bohutinsky 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act which provides for the potential exercise of vested stock options and the associated sale of up to 15,000 shares of the Company’s Class A common stock. The Bohutinsky 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 31, 2024, (2) the date on which an aggregate of 15,000 shares of the Company’s Class A common stock have been sold under the Bohutinsky 10b5-1 Sales Plan, or (3) such time as the Bohutinsky 10b5-1 Sales Plan is otherwise terminated or expires according to its terms. | |||||
| Dr. Luis von Ahn, Chief Executive Officer |
Adopted 10b5-1 plan | Nov 30, 2023 | 10-K Feb 29, 2024 | ||
What the company wroteOn November 30, 2023, Dr. Luis von Ahn, Chief Executive Officer, and the Luis von Ahn Foundation, of which Dr. von Ahn is the Director and President, entered into a 10b5-1 sales plan (the “von Ahn 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act, pursuant to which a maximum aggregate of 103,000 shares of the Company’s Class A common stock may be sold (up to 80,000 shares by Dr. von Ahn and up to 23,000 by the Luis von Ahn Foundation). The von Ahn 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 15, 2024, (2) the date on which an aggregate of 103,000 shares of the Company’s common stock have been sold under the von Ahn 10b5-1 Sales Plan, or (3) such time as the von Ahn 10b5-1 Sales Plan is otherwise terminated or expires according to its terms. | |||||
| Stephen Chen General Counsel |
Ended 10b5-1 plan | Sep 11, 2023 | 10-Q Nov 9, 2023 | ||
What the company wroteOn September 11, 2023, the 10b5-1 sales plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act entered into by Stephen Chen, General Counsel, on June 2, 2023 expired in accordance with its terms upon the sale of the maximum aggregate number of shares of Class A common stock covered by such plan. On September 15, 2023, Mr. Chen entered into a 10b5-1 sales plan (the “Chen 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act which provides for the potential exercise of vested stock options and the associated sale of up to 20,000 shares of the Company’s Class A common stock. The Chen 10b5-1 Sales Plan will remain in effect until the earlier of (1) July 31, 2024, (2) the date on which an aggregate of 20,000 shares of the Company’s Class A common stock have been sold under the Chen 10b5-1 Sales Plan, or (3) such time as the Chen 10b5-1 Sales Plan is otherwise terminated or expires according to its terms. | |||||
| Robert Meese Chief Business Officer |
Adopted 10b5-1 plan | Sep 8, 2023 | 10-Q Nov 9, 2023 | ||
What the company wroteOn September 8, 2023, Robert Meese, Chief Business Officer, entered into a 10b5-1 sales plan (the “Meese 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act which provides for the sale of up to 40,000 shares of the Company’s Class A common stock. The Meese 10b5-1 Sales Plan will remain in effect until the earlier of (1) October 31, 2024, (2) the date on which an aggregate of 40,000 shares of the Company’s common stock have been sold under the Meese 10b5-1 Sales Plan, or (3) such time as the Meese 10b5-1 Sales Plan is otherwise terminated or expires according to its terms. | |||||
| Natalie Glance Chief Engineering Officer |
Adopted 10b5-1 plan | Sep 5, 2023 | 10-Q Nov 9, 2023 | ||
What the company wroteOn September 5, 2023, Natalie Glance, Chief Engineering Officer, entered into a 10b5-1 sales plan (the “Glance 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act which provides for the sale of up to 60,000 shares of the Company’s Class A common stock. The Glance 10b5-1 Sales Plan will remain in effect until the earlier of (1) December 31, 2024, (2) the date on which an aggregate of 60,000 shares of the Company’s Class A common stock have been sold under the Glance 10b5-1 Sales Plan, or (3) such time as the Glance 10b5-1 Sales Plan is otherwise terminated or expires according to its terms. | |||||
| Matthew Skaruppa Chief Financial Officer |
Ended 10b5-1 plan | Jun 9, 2023 | 10-Q Aug 9, 2023 | ||
What the company wroteOn June 9, 2023, Matthew Skaruppa, Chief Financial Officer, modified an existing trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act, originally adopted on September 8, 2022 (the “Original Skaruppa 10b5-1 Sales Plan”), to modify the amount of shares, price limits and timing of sales under the plan. The Original Skaruppa 10b5-1 Sales Plan provided for (i) the potential exercise of vested stock options and the associated sale of up to 76,000 shares of the Company’s Class A common stock and (ii) the sale of the net number of shares of Class A common stock underlying 17,315 restricted stock units received after giving effect to the number of shares sold to satisfy tax withholding obligations on each vesting date specified under the Original Skaruppa 10b5-1 Sales Plan (such total number of shares covered under clause (ii) is not determinable). Prior to its termination, 41,764 shares of Class A common Stock were sold pursuant to the Original Skaruppa 10b5-1 Sales Plan, and an aggregate of 44,000 shares of Class A underlying vested stock options remained unsold and 7,551 restricted stock units remained unvested. The modified trading arrangement (the “Skaruppa 10b5-1 Sales Plan”) is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and provides for (i) the potential exercise of vested stock options and the associated sale of up to 100,000 shares of the Company’s Class A common stock and, (ii) the sale of the net number of shares of Class A common stock underlying 20,664 restricted stock units received after giving effect to the number of shares sold to satisfy tax withholding obligations on each vesting date specified under the Skaruppa 10b5-1 Sales Plan (such total number of shares covered under clause (ii) is not determinable), and (iii) the sale of 1,155 shares of Class A common stock shares that remained unsold under the Original Skaruppa 10b5-1 Sales Plan. The Skaruppa 10b5-1 Sales Plan will remain in effect until the earlier of August 14, 2024, (2) the date on which all trades set forth in the Skaruppa 10b5-1 Sales Plan have been executed, or (3) such time as the Skaruppa 10b5-1 Sales Plan is otherwise terminated according to its terms. | |||||
| Severin Hacker Chief Technology Officer and director |
Adopted 10b5-1 plan | Jun 2, 2023 | 10-Q Aug 9, 2023 | ||
What the company wroteOn June 2, 2023, the SBH Trust dated March 10, 2020 (the “SBH Trust”) and the Hacker Charitable Trust, of which Dr. Severin Hacker, Chief Technology Officer and director, is the Trustee, entered into a joint 10b5-1 sales plan (the “Hacker 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act, pursuant to which a maximum aggregate of 190,000 shares of the Company’s Class A common stock may be sold (up to 120,000 shares by the SBH Trust and up to 70,000 by the Hacker Charitable Trust). The Hacker 10b5-1 Sales Plan will remain in effect until the earlier of (1) September 30, 2024, (2) upon the completed sale of an aggregate of 190,000 shares of the Company’s Class A common stock have been sold under the Hacker 10b5-1 Sales Plan, or (3) such time as the Hacker 10b5-1 Sales Plan is otherwise terminated according to its terms. | |||||
| Stephen Chen General Counsel |
Adopted 10b5-1 plan | Jun 2, 2023 | 10-Q Aug 9, 2023 | ||
What the company wroteOn June 2, 2023, Stephen Chen, General Counsel, entered into a 10b5-1 sales plan (the “Chen 10b5-1 Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act which provides for the potential exercise of vested stock options and the associated sale of up to 14,167 shares of the Company’s Class A common stock. The Chen 10b5-1 Sales Plan will remain in effect until the earlier of (1) May 31, 2024, (2) the date on which an aggregate of 14,167 shares of the Company’s common stock have been sold under the Chen 10b5-1 Sales Plan, or (3) such time as the Chen 10b5-1 Sales Plan is otherwise terminated according to its terms. | |||||
Show the other 23 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 16 filings checked since May 10, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Nov 4, 2026 | STEPHEN CHEN Officer |
3,700 | $474K |
| Oct 7, 2026 | LUIS VON AHN ARELLANO Director, Officer, 10% Stockholder |
110,046 | $16.3M |
| Sep 24, 2026 | LUIS VON AHN ARELLANO Director, Officer, 10% Stockholder |
46,682 | $6.8M |
| Sep 22, 2026 | LUIS VON AHN ARELLANO Director, Officer, 10% Stockholder |
3,614 | $540K |
| Sep 21, 2026 | LUIS VON AHN FOUNDATION Director, Officer, 10% Stockholder |
34,992 | $5.0M |
| Sep 21, 2026 | LUIS VON AHN ARELLANO Director, Officer, 10% Stockholder |
37,366 | $5.3M |
| Sep 16, 2026 | LUIS VON AHN ARELLANO Director, Officer, 10% Stockholder |
28,292 | $4.4M |
| Sep 16, 2026 | LUIS VON AHN FOUNDATION Director, Officer, 10% Stockholder |
19,008 | $2.9M |
| Sep 14, 2026 | STEPHEN CHEN Officer |
8,072 | $1.2M |
| Sep 8, 2026 | WILLIAM B. GORDON Director |
20,000 | $3.1M |
| Aug 18, 2026 | NATALIE GLANCE Officer |
1,539 | $200K |
| Aug 17, 2026 | STEPHEN CHEN Officer |
1,024 | $132K |
| Aug 17, 2026 | NATALIE GLANCE Officer |
2,751 | $355K |
| Aug 17, 2026 | ROBERT MEESE Officer |
1,354 | $175K |
| May 18, 2026 | NATALIE GLANCE Officer |
3,360 | $377K |
| May 18, 2026 | STEPHEN CHEN Officer |
1,977 | $222K |
| May 15, 2026 | ROBERT MEESE Officer |
1,420 | $159K |
| May 15, 2026 | STEPHEN CHEN Officer |
820 | $92K |
| May 15, 2026 | NATALIE GLANCE Officer |
1,929 | $216K |
| Feb 18, 2026 | STEPHEN CHEN Officer |
1,901 | $213K |
| Feb 18, 2026 | MATTHEW SKARUPPA Officer |
3,986 | $447K |
| Feb 18, 2026 | NATALIE GLANCE Officer |
3,545 | $397K |
| Feb 17, 2026 | MATTHEW SKARUPPA Officer |
1,870 | $206K |
| Feb 17, 2026 | NATALIE GLANCE Officer |
1,741 | $192K |
| Feb 17, 2026 | STEPHEN CHEN Officer |
896 | $99K |
| Feb 17, 2026 | ROBERT MEESE Officer |
1,000 | $110K |
| Dec 12, 2025 | THE SEVERIN HACKER FOUNDATIONC/O PHILIP BARTELS Director, Officer, 10% Stockholder |
10,000 | $2.0M |
| Nov 18, 2025 | MATTHEW SKARUPPA Officer |
3,059 | $545K |
| Nov 18, 2025 | STEPHEN CHEN Officer |
1,514 | $270K |
| Nov 18, 2025 | NATALIE GLANCE Officer |
2,471 | $441K |
| Nov 17, 2025 | ROBERT MEESE Officer |
1,444 | $257K |
| Nov 17, 2025 | NATALIE GLANCE Officer |
2,534 | $451K |
| Nov 17, 2025 | STEPHEN CHEN Officer |
1,282 | $228K |
| Nov 17, 2025 | MATTHEW SKARUPPA Officer |
2,799 | $498K |
Show the other 26 notices
From the Form 144 XML filed with the SEC, since Nov 17, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/DUOL/export.csv") into a cell.